Your browser doesn't support javascript.
Neutralizing antibody titres in SARS-CoV-2 infections.
Lau, Eric H Y; Tsang, Owen T Y; Hui, David S C; Kwan, Mike Y W; Chan, Wai-Hung; Chiu, Susan S; Ko, Ronald L W; Chan, Kin H; Cheng, Samuel M S; Perera, Ranawaka A P M; Cowling, Benjamin J; Poon, Leo L M; Peiris, Malik.
  • Lau EHY; School of Public Health, The University of Hong Kong, Special Administrative Region of Hong Kong, Hong Kong, China.
  • Tsang OTY; Infectious Diseases Centre, Princess Margaret Hospital, Hospital Authority of Hong Kong, Special Administrative Region of Hong Kong, Hong Kong, China.
  • Hui DSC; Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China.
  • Kwan MYW; Department of Paediatric and Adolescent Medicine, Princess of Margaret Hospital, Hospital Authority of Hong Kong, Special Administrative Region of Hong Kong, Hong Kong, China.
  • Chan WH; Department of Paediatrics, Queen Elizabeth Hospital, Hospital Authority of Hong Kong, Special Administrative Region of Hong Kong, Hong Kong, China.
  • Chiu SS; Department of Paediatric and Adolescent Medicine, The University of Hong Kong and Queen Mary Hospital, Hospital Authority of Hong Kong, Special Administrative Region of Hong Kong, Hong Kong, China.
  • Ko RLW; School of Public Health, The University of Hong Kong, Special Administrative Region of Hong Kong, Hong Kong, China.
  • Chan KH; School of Public Health, The University of Hong Kong, Special Administrative Region of Hong Kong, Hong Kong, China.
  • Cheng SMS; School of Public Health, The University of Hong Kong, Special Administrative Region of Hong Kong, Hong Kong, China.
  • Perera RAPM; School of Public Health, The University of Hong Kong, Special Administrative Region of Hong Kong, Hong Kong, China.
  • Cowling BJ; School of Public Health, The University of Hong Kong, Special Administrative Region of Hong Kong, Hong Kong, China.
  • Poon LLM; School of Public Health, The University of Hong Kong, Special Administrative Region of Hong Kong, Hong Kong, China.
  • Peiris M; School of Public Health, The University of Hong Kong, Special Administrative Region of Hong Kong, Hong Kong, China. malik@hku.hk.
Nat Commun ; 12(1): 63, 2021 01 04.
Article in English | MEDLINE | ID: covidwho-1007631
ABSTRACT
The SARS-CoV-2 pandemic poses the greatest global public health challenge in a century. Neutralizing antibody is a correlate of protection and data on kinetics of virus neutralizing antibody responses are needed. We tested 293 sera from an observational cohort of 195 reverse transcription polymerase chain reaction (RT-PCR) confirmed SARS-CoV-2 infections collected from 0 to 209 days after onset of symptoms. Of 115 sera collected ≥61 days after onset of illness tested using plaque reduction neutralization (PRNT) assays, 99.1% remained seropositive for both 90% (PRNT90) and 50% (PRNT50) neutralization endpoints. We estimate that it takes at least 372, 416 and 133 days for PRNT50 titres to drop to the detection limit of a titre of 110 for severe, mild and asymptomatic patients, respectively. At day 90 after onset of symptoms (or initial RT-PCR detection in asymptomatic infections), it took 69, 87 and 31 days for PRNT50 antibody titres to decrease by half (T1/2) in severe, mild and asymptomatic infections, respectively. Patients with severe disease had higher peak PRNT90 and PRNT50 antibody titres than patients with mild or asymptomatic infections. Age did not appear to compromise antibody responses, even after accounting for severity. We conclude that SARS-CoV-2 infection elicits robust neutralizing antibody titres in most individuals.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Limits: Adolescent / Adult / Animals / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Asia Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-020-20247-4

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Limits: Adolescent / Adult / Animals / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: Asia Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-020-20247-4